Severely Prolonged Vancomycin Half-life in a Patient with Normal Serum Creatinine and Creatinine Clearance
Jeffrey W. Jansen1,2★, Ryan P. Moenster3,4★ Corresponding author
- 1Department of Pharmacy, Saint Vincent Healthcare, Billings, MT, USA.
- 2Research, VA Saint Louis Health Care System, Saint Louis, MO, USA.
- 3Pharmacy, VA Saint Louis Health Care System, Saint Louis, MO, USA.
- 4Department of Pharmacy Practice, Saint Louis College of Pharmacy, Saint Louis, MO, USA.
CORRESPONDENCE
Jeffrey W. Jansen
Department of Pharmacy, Saint Vincent Healthcare, Billings, MT, USA.
Received: 21-08-2017; Revised: 22-12-2017; Accepted: 11-12-2017.
Volume 9, Issue 1 · pp. 52–5 · PUBLISHED 2018 · DOI: 10.4103/jpp.JPP_101_17
View on J Pharmacol. Pharmacother. original site ↗
ABSTRACT
Vancomycin remains the antibiotic of choice to treat resistant Gram-positive infections and is dosed utilizing weight-based protocols or pharmacokinetic calculations. Pharmacokinetic calculations are a more proactive approach to vancomycin dosing but are occasionally limited as certain patient-specific variables such as volume of distribution, renal function, and severity of illness do not allow all patients to follow population estimates. In these situations, if the above-mentioned variables are adjusted for an individual patient rather than the population estimates, the kinetic models reflect accurate vancomycin dosing. We present a patient with apparently normal renal function (Cockcroft-Gault) following a significant renal injury who had sustained supratherapeutic vancomycin serum concentrations and a calculated peak elimination half-life of 346 h. Importantly, this patient had adequate clearance of other highly renally eliminated medications (digoxin and meropenem), which suggests limited long-term deficit due to the previous sustained renal injury. In this patient case, vancomycin’s chemical properties and pharmacokinetics are explored to best explain the patient’s highly unusual response. In addition, an analysis of vancomycin’s less well-described pharmacokinetics such as active secretion, tubular reabsorption, and nonrenal elimination pathways is explored. Ultimately, this patient represents a perplexing case which highlights the continued need for therapeutic drug monitoring with vancomycin.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Jansen, J. W., & Moenster, R. P. (2018). Severely Prolonged Vancomycin Half-life in a Patient with Normal Serum Creatinine and Creatinine Clearance. Journal of Pharmacology and Pharmacotherapeutics, 9(1), 52–5. https://doi.org/10.4103/jpp.JPP_101_17